Response to Comment on 'Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin'
| Autor: | Xiaoli Zheng, Huidi Jiang, Fuqing Tan, Qinqin Yu, Lushan Yu, Lingmin Yuan, Yanqing Liu, Hua Wang, Su Zeng, Qianying Zhu |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Epigenomics
0301 basic medicine Organoplatinum Compounds business.industry Decitabine General Medicine Pharmacology Drug transporter medicine.disease Kidney Neoplasms Oxaliplatin 03 medical and health sciences 030104 developmental biology Renal cell carcinoma Cell culture Carcinoma Humans Medicine Epigenetics business Carcinoma Renal Cell medicine.drug |
| Zdroj: | Science Translational Medicine. 9 |
| ISSN: | 1946-6242 1946-6234 |
| DOI: | 10.1126/scitranslmed.aam6298 |
| Popis: | OCT2 plays a key role in synergy between decitabine and oxaliplatin in renal cell carcinoma cell lines. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|